A comparative analysis of alterations in protein expression after activation or human immunodeficiency virus, type 1 infection of human CD4+ T cells.
We have previously described an in vitro model for studying human immunodeficiency virus, type 1 (HIV-1) infection in CD4+ T cells [1]. This model employs the WE17/10 cell line, which loses expression of its T cell receptor/CD3 (TCR/CD3) after several months of productive infection. We have used this model to analyze the synthesis and posttranslational modification of viral and cellular proteins after HIV-1 infection and to determine the relationship of these changes to TCR/CD3 expression. Mainly we observe positive changes in protein expression after infection. A phosphoprotein, referred to as WH:1, appears in infected cells that still express their TCR/CD3 complex, and its persistence is linked to the presence of the complex. We examined whether loss of the TCR/CD3 complex could be associated with alterations in the T cell activation pathway as a result of infection. We used T cell activators and inhibitors to determine whether there were common elements between the two events. Quantitative enhancement in one spot, Cs:1, occurred after both Cyclosporin A treatment of uninfected cells and HIV-1 infection of untreated cells. Taken altogether, these data suggest that a correlation exists between negative regulation of late events in the T cell activation pathway and down regulation of the TCR/CD3 complex after HIV-1 infection.
International Institute of Cellular and Molecular Pathology, Brussels, Belgium.
F
F
Van de Keere
K E
KE
Willard-Gallo
D000470:Alkaloids / Q000494:pharmacology; D015703:Antigens, CD / Q000032:analysis*; D001345:Autoradiography / Q000379:methods; D015704:CD4 Antigens / Q000032:analysis / Q000276:immunology*; D002460:Cell Line; D016572:Cyclosporine / Q000494:pharmacology; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods; D015497:HIV-1 / Q000276:immunology*; D006681:HLA-D Antigens / Q000032:analysis; D015395:Histocompatibility Antigens Class I / Q000032:analysis; D006801:Humans; D008213:Lymphocyte Activation; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D019311:Staurosporine; D013462:Sulfur Radioisotopes; D016176:T-Lymphocyte Subsets / Q000737:chemistry / Q000187:drug effects / Q000276:immunology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D000470:Alkaloids; D015703:Antigens, CD; D015704:CD4 Antigens; D006681:HLA-D Antigens; D015395:Histocompatibility Antigens Class I; D013462:Sulfur Radioisotopes; D016572:Cyclosporine; D011493:Protein Kinase C; D019311:Staurosporine; D013755:Tetradecanoylphorbol Acetate